VITAE Biomedical

Detection Technology

About Service

About Cost

Q：How is this test conducted?

A：We collect your urine specimen for this test.

Q：What types of cancer can this test detect, and what method is used?

A：This technology detects a specific protein molecular marker in urine through specific antibodies developed by VITAE, which is used as a reference for identifying potential lung cancer patients.

Q：Can this test detect all types of lung cancer?

A： Clinical studies have shown that this technology can detect a specific cancer-associated molecule in patients with Adenocarcinoma, Squamous Cell Carcinoma, and Small Cell Lung Cancer.

Q：What are the requirements for urine collection?

A：We recommend collecting the first morning urine. If collecting at other times, refrain from drinking any liquids for at least 1 hour prior to collection to avoid diluting the urine specimen. Ensure you collect the middle section of the urine, with at least 10 ml.

Q：Can kidney diseases affect the test result?

A：Our detection technology is highly specific for lung cancer-associated biomarkers. However, it is not recommended for patients with chronic kidney disease due to metabolic disturbances that may affect the biosignatures in the urine.

Q：Should imaging techniques be used if higher-than-normal levels of lung cancer biomarkers are identified in my sample?

A：This detection technology provides doctors with supporting evidence for lung cancer risks. Based on the results, doctors may recommend follow-up tests such as LDCT or standard-dose CT scans, to locate any tumors.

Q：What is the difference between Vitae's urine test technology and general genetic screening on the market?

A：Genetic screenings involve amplifying genetic sequences to study the relationships between genes (or their mutations) and diseases, primarily for cancer patients seeking targeted therapies. However, they are not widely accepted for early-stage cancer screenings due to concerns over sensitivity and they typically require a blood draw or invasive biopsy.
The Vitae Test, on the other hand, detects protein molecules in urine, eliminating the need for venipuncture. These protein expressions reflect the real-time risk status of patients.

Q：What are the advantages of Vitae's detection technology compared to LDCT for lung cancer screening?

A：While LDCT scans can detect pulmonary nodules smaller than 1 cm, they may lead to overdiagnosis and unnecessary invasive procedures or follow-up tests. The Vitae Test, unlike imaging methods, has minimal side effects and can be repeated for risk assessment purposes.

Q：How should the urine specimen be preserved?

A：To ensure specimen integrity, it is highly recommended to store it at -20°C immediately after collection.

Q： How long can the urine specimen be stored?

A：If the specimen is stored at -20°C immediately after collection, it can be sent to the VITAE Lab within one week.

Q：How long will it take to receive the result report?

A：Approximately 10 working days.

Q：Will VITAE refer doctors when the detection result shows a very high risk?

A：We will introduce you to a doctor or hospital. If your examination was performed with your doctor, please contact your doctor directly.

Q：As air pollution becomes more serious, how can this detection technology help reduce lung cancer mortality?

A：Lung cancer is the leading cause of cancer deaths in Taiwan, affecting both high-risk groups and the general population over the age of 45. With no obvious early symptoms, about 57.9% of confirmed cases are already in stage 4 and cannot be treated effectively, resulting in a five-year survival rate of less than 20%. Early detection, when lung cancer is in stage 1 or 2, can raise the five-year survival rate to as high as 80%. VITAE's detection technology enables the early identification of cancer-associated biomarkers for a wider population, thereby reducing mortality in the long term.

Q：Will an LDCT scan performed before the urine test interfere with the detection result? Are there other factors that may affect the detection result?

A：Low-dose computerized tomography (LDCT) is an imaging technology that will not interfere with the urine specimen. This urine test is not recommended for those with abnormal kidney function. Please eat and rest normally before the test, avoid foods high in protein, and refrain from excessive drinking or exercise. Inform us if you are taking any medication.

Q：Can this result report be used by doctors as a basis for the diagnosis and treatment of lung cancer?

A：This detection technology provides doctors with supporting evidence for lung cancer risk assessment. At the moment, it cannot be used as a basis for treatment options such as targeted therapy or chemotherapy drugs.

Q：Does national health insurance cover the detection cost?

A：Currently, the detection service is paid out of pocket. It may be covered by health insurance policies in the future.